
A prominent player in the pharmaceutical and biotech industry with a market cap of $7.14 billion, Catalent, Inc. (CTLT) specializes in the development and manufacturing of solutions for a wide range of products, including drugs, protein-based biologics, cell and gene therapies, and consumer health items on a global scale.
CTLT operates in several segments within the pharmaceutical and healthcare industry, including Softgel and Oral Technologies; Biologics; Oral and Specialty Delivery; and Clinical Supply Services. In addition, it extends its services to other healthcare market segments, such as animal health, medical devices, and cosmetics industries.